KRAS and cancer: Importantly, KRAS-mutant cancer cells differing in EMT status vary in their responses to MEK inhibitors (26), as EMT rewires the expression of receptor tyrosine kinases (RTKs), a consequence of differential feedback activation of the MAPK pathway following MEK inhibition.